Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
3.950
+0.180 (4.77%)
At close: May 3, 2024, 4:00 PM
3.930
-0.020 (-0.51%)
After-hours: May 3, 2024, 7:23 PM EDT
Revance Therapeutics Revenue
In the year 2023, Revance Therapeutics had annual revenue of $234.04M with 76.55% growth. Revenue in the quarter ending December 31, 2023 was $69.80M with 39.82% year-over-year growth.
Revenue (ttm)
$234.04M
Revenue Growth
+76.55%
P/S Ratio
1.76
Revenue / Employee
$392,027
Employees
597
Market Cap
411.65M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 234.04M | 101.48M | 76.55% |
Dec 31, 2022 | 132.57M | 54.77M | 70.40% |
Dec 31, 2021 | 77.80M | 62.47M | 407.65% |
Dec 31, 2020 | 15.33M | 14.91M | 3,610.65% |
Dec 31, 2019 | 413.00K | -3.32M | -88.92% |
Dec 31, 2018 | 3.73M | 3.47M | 1,323.28% |
Dec 31, 2017 | 262.00K | -38.00K | -12.67% |
Dec 31, 2016 | 300.00K | - | - |
Dec 31, 2015 | 300.00K | -83.00K | -21.67% |
Dec 31, 2014 | 383.00K | -234.00K | -37.93% |
Dec 31, 2013 | 617.00K | -100.00K | -13.95% |
Dec 31, 2012 | 717.00K | 160.00K | 28.73% |
Dec 31, 2011 | 557.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
OraSure Technologies | 405.47M |
Anika Therapeutics | 166.66M |
NeuroPace | 65.42M |
MaxCyte | 41.29M |
Cartesian Therapeutics | 26.00M |
RVNC News
- 1 day ago - Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Business Wire
- 21 days ago - Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting - Business Wire
- 4 weeks ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 5 weeks ago - Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Revance Announces Pricing of $100.0 Million Public Offering of Common Stock - Business Wire
- 2 months ago - Revance Announces Proposed Public Offering of Common Stock - Business Wire
- 2 months ago - Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update - Business Wire
- 2 months ago - Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 - Business Wire